Familial hypercholesterolaemia
KEYWORDS: people, diagnosis, quality, statement, data, treatment, testing, clinical, children, specialist, hypercholesterolaemia, familial hypercholesterolaemia, clinical diagnosis, familial, source

with FH. Data source: Local data collection. Outcome Number of adults with FH whose LDL-C concentration is reduced by more than 50% from baseline within 1 year. Data source: Local data collection using a dedicated database. What the quality statement means for different audiences Service providers ensure that systems are in place for adults with FH to receive lipid-modifying drug treatment to reduce LDL-C concentration by more than 50% from baseline. Healthcare practitioners offer adults with FH lipid-modifying drug treatment to reduce LDL-C concentration by more than 50% from baseline. Commissioners ensure that they commission services that offer adults with FH lipid-modifying drug treatment to reduce LDL-C concentration by more than 50% from baseline. Adults with FH are offered drugs to reduce the low-density cholesterol (bad cholesterol) in their blood to less than a half of the level before treatment. Source guidance Familial hypercholesterolaemia: identification and management. NICE guideline CG71 (2008, updated 2019), recommendations 1.3.1.2 to 1.3.1.4, 1.3.1.6 to 1.3.1.8 and 1.3.1.14 Definitions of terms used in this quality statement Familial hypercholesterolaemia (FH) FH relates to heterozygous FH only. Adults with FH Adults (aged 16 and older) should have a diagnosis of FH made by a specialist with expertise in
